
    
      Patients in the camrelizumab group were treated with camrelizumab with the dose of 200mg on
      day 1, repeated every 21 days.Patients in the combination group were treated with MWA in the
      primary tumor followed by camrelizumab with the dose of 200mg on day 1, repeated every 21
      days.

      The primary end point is overall survival. The second end points include progression free
      survival, objective response rate and safety.
    
  